Author = Mahdi Behdani
In vitro evaluation of anti-angiogenesis property of anti-VEGFR2 nanobody-conjugated H40-PEG carrier loaded with methotrexate

Volume 25, Issue 12, December 2022, Pages 1477-1486

10.22038/ijbms.2022.67038.14701

Seyed Masih Adyani; Hamid Rashidzadeh; Mahdi Behdani; Seyed Jamal Tabatabaei Rezaei; Ali Ramazani


Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function

Volume 21, Issue 3, March 2018, Pages 260-266

10.22038/ijbms.2018.24898.6183

Fatemeh Kazemi-Lomedasht; serge muyldermans; Mahdi Habibi-Anbouhi; Mahdi Behdani


In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies

Volume 20, Issue 5, May 2017, Pages 489-496

10.22038/ijbms.2017.8672

vFatemeh Kazemi-Lomedasht v; Kamran Pooshang-Bagheri; Mahdi Habibi-Anbouhi; Ensiyeh Hajizadeh-Safar; Delavar Shahbazzadeh; Hasan Mirzahosseini; Mahdi Behdani


Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)

Volume 19, Issue 11, November 2016, Pages 1201-1208

10.22038/ijbms.2016.7820

Vida Homayouni; Mazdak Ganjalikhani-hakemi; Abbas Rezaei; Hossein Khanahmad; Mahdi Behdani; Fatemeh Kazemi Lomedasht